--- title: "MOTS-c vs SS-31 | PepTracker Pro" url: https://peptrackerpro.com/compare/mots-c-vs-ss-31 description: "MOTS-c and SS-31 both target mitochondrial function but through entirely different mechanisms — MOTS-c as an endogenous signaling peptide and SS-31 as a synthetic membrane-targeting compound." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This comparison is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # MOTS-c vs SS-31 Last updated: 2026-07-17 - MOTS-c is a mitochondrial-derived peptide encoded by mitochondrial DNA; SS-31 (Elamipretide) is a synthetic peptide that targets cardiolipin in the inner mitochondrial membrane. - MOTS-c research focuses on metabolic regulation and exercise mimetic effects; SS-31 research emphasizes mitochondrial dysfunction and cardioprotection. - SS-31 has advanced further in clinical trials, including Phase 2/3 studies for Barth syndrome and heart failure. - MOTS-c activates AMPK and influences glucose metabolism; SS-31 stabilizes the electron transport chain by binding cardiolipin. - Both represent a growing field of mitochondria-targeted peptide therapeutics. MOTS-c and SS-31 both target mitochondrial function but through entirely different mechanisms — MOTS-c as an endogenous signaling peptide and SS-31 as a synthetic membrane-targeting compound. ## Side-by-Side Comparison | Attribute | MOTS-c | SS-31 | | --- | --- | --- | | What It Is | A mitochondrial-derived peptide studied for metabolic regulation, exercise mimetic effects, and longevity. | A mitochondria-targeted peptide FDA-approved as FORZINITY (elamipretide) for Barth syndrome in September 2025 — the first FDA-approved mitochondrial-targeted therapeutic. | | Typical Research Focus | MetabolismFat LossLongevityMuscle GrowthAnti-AgingEnergy | LongevityAnti-AgingRecoveryNeuroprotection | | Proposed Mechanisms | Not yet documented | Not yet documented | | Evidence Snapshot | Low Evidence research peptide | High Evidence prescription drug | | Cautions | - Discovery is recent; most data is preclinical - No completed human clinical trials - Long-term effects unknown | - FDA-approved only for Barth syndrome; other indications remain investigational - Accelerated approval pathway — confirmatory trials may be required - Off-label use for anti-aging or longevity not supported by clinical evidence | ### MOTS-c What It Is A mitochondrial-derived peptide studied for metabolic regulation, exercise mimetic effects, and longevity. Research Focus MetabolismFat LossLongevityMuscle GrowthAnti-AgingEnergy Evidence Low Evidence Cautions - Discovery is recent; most data is preclinical - No completed human clinical trials - Long-term effects unknown ### SS-31 What It Is A mitochondria-targeted peptide FDA-approved as FORZINITY (elamipretide) for Barth syndrome in September 2025 — the first FDA-approved mitochondrial-targeted therapeutic. Research Focus LongevityAnti-AgingRecoveryNeuroprotection Evidence High Evidence Cautions - FDA-approved only for Barth syndrome; other indications remain investigational - Accelerated approval pathway — confirmatory trials may be required - Off-label use for anti-aging or longevity not supported by clinical evidence ## When Researchers Compare Them MOTS-c and SS-31 represent two distinct approaches to mitochondrial therapeutics. MOTS-c is an endogenous mitochondrial-derived peptide (MDP), meaning it is naturally encoded within mitochondrial DNA. Research has shown it activates AMPK, enhances glucose uptake, and may function as an exercise mimetic — making it a subject of interest in metabolic disease and aging research. SS-31 (also known as Elamipretide or Bendavia) is a synthetic tetrapeptide designed to penetrate cell membranes and selectively bind cardiolipin, a phospholipid critical to the inner mitochondrial membrane. By stabilizing the electron transport chain, SS-31 aims to restore mitochondrial efficiency in conditions where mitochondrial dysfunction is a driver of disease. SS-31 has progressed further in the clinical pipeline, with Phase 2 and 3 trials conducted in Barth syndrome, age-related macular degeneration, and heart failure with preserved ejection fraction. MOTS-c research remains primarily preclinical but is rapidly expanding. ## Peptide Profiles MOTS-c Profile: https://peptrackerpro.com/peptides/mots-c SS-31 Profile: https://peptrackerpro.com/peptides/ss-31 ## Citations 1. [1] Lee C. et al. — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metab. 2015 Source (https://pubmed.ncbi.nlm.nih.gov/) 2. [2] Lee C. et al. — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metab. 2015 Source (https://pubmed.ncbi.nlm.nih.gov/25738459/) 3. [3] MOTS-c prevents pancreatic islet cell senescence to delay diabetes — Exp Mol Med. 2025 Source (https://www.nature.com/articles/s12276-025-01521-1) 4. [4] MOTS-c restores mitochondrial respiration in type 2 diabetic heart — Frontiers Physiol. 2025 Source (https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2025.1602271/full) 5. [5] MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline — Nature Commun. 2021 Source (https://www.nature.com/articles/s41467-020-20790-0) 6. [6] MOTS-c in type 2 diabetes mellitus: From risk factors to cardiac complications — Life Sciences 2026 Source (https://www.sciencedirect.com/science/article/abs/pii/S0024320525006459) 7. [7] FDA — July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee Source (https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) 8. [8] STAT — An obesity drug deep-dive, and peptides move mainstream (June 11, 2026) Source (https://www.statnews.com/2026/06/11/an-obesity-drug-deep-dive-and-peptides-move-mainstream/) 9. [9] FDA Approves FORZINITY (elamipretide) for Barth Syndrome — Stealth BioTherapeutics, September 2025 Source (https://stealthbt.com/stealth-biotherapeutics-announces-fda-accelerated-approval-of-forzinity-elamipretide-hcl/) 10. [10] UMDF — FDA Approves First Mitochondrial Disease Therapy Source (https://umdf.org/fda-approves-elamipretide/) 11. [11] Johns Hopkins Hub — FDA approves drug for Barth syndrome, September 2025 Source (https://hub.jhu.edu/2025/09/25/fda-approves-barth-syndrome-treatment/) 12. [12] Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential — IJMS. 2026 Source (https://www.mdpi.com/1422-0067/26/3/944) 13. [13] SS-31 treatment ameliorates cardiac mitochondrial morphology in Barth syndrome model — Scientific Reports. 2024 Source (https://www.nature.com/articles/s41598-024-64368-y) ### Explore Research Tools Use calculators for reconstitution, dosing references, and more. Use PepTracker Pro Tools (https://peptrackerpro.com/calculators) ## Related Peptides ### 5-Amino-1MQ Low Evidence A small molecule NNMT inhibitor studied for metabolic enhancement and fat cell reduction. Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism Energy: https://peptrackerpro.com/benefits/energy View Details: https://peptrackerpro.com/peptides/5-amino-1mq \+ Compare: https://peptrackerpro.com/compare?select=5-amino-1mq Track in App: https://app.peptrackerpro.com/?add=5-amino-1mq ### Epithalon Low Evidence A tetrapeptide studied for its potential to activate telomerase and influence biological aging markers. Longevity: https://peptrackerpro.com/benefits/longevity Anti-Aging: https://peptrackerpro.com/benefits/anti-aging Sleep: https://peptrackerpro.com/benefits/sleep Immune Support: https://peptrackerpro.com/benefits/immune-support View Details: https://peptrackerpro.com/peptides/epithalon \+ Compare: https://peptrackerpro.com/compare?select=epithalon Track in App: https://app.peptrackerpro.com/?add=epithalon ### Humanin Low Evidence An endogenous mitochondrial-derived peptide studied for neuroprotection, cellular stress resistance, and longevity, whose blood levels fall with age and are elevated in centenarians. Longevity (https://peptrackerpro.com/benefits/longevity)Anti-Aging (https://peptrackerpro.com/benefits/anti-aging)Neuroprotection (https://peptrackerpro.com/benefits/neuroprotection)Metabolism (https://peptrackerpro.com/benefits/metabolism)+1 more View Details: https://peptrackerpro.com/peptides/humanin \+ Compare: https://peptrackerpro.com/compare?select=humanin Track in App: https://app.peptrackerpro.com/?add=humanin ### Motixafortide (Aphexda) High Evidence An FDA-approved synthetic cyclic peptide and CXCR4 antagonist (brand name Aphexda; research name BL-8040) used together with G-CSF to mobilize blood-forming stem cells for autologous transplant in multiple myeloma. In 2026 it is being actively studied as part of combination immunotherapy for pancreatic cancer. Hematology: https://peptrackerpro.com/benefits/hematology Oncology: https://peptrackerpro.com/benefits/oncology Immune Modulation: https://peptrackerpro.com/benefits/immune-modulation View Details: https://peptrackerpro.com/peptides/motixafortide \+ Compare: https://peptrackerpro.com/compare?select=motixafortide Track in App: https://app.peptrackerpro.com/?add=motixafortide ### NAD+ Medium Evidence A coenzyme essential for cellular energy production, studied for anti-aging and metabolic support. Energy (https://peptrackerpro.com/benefits/energy)Longevity (https://peptrackerpro.com/benefits/longevity)Anti-Aging (https://peptrackerpro.com/benefits/anti-aging)Metabolism (https://peptrackerpro.com/benefits/metabolism)+1 more View Details: https://peptrackerpro.com/peptides/nad \+ Compare: https://peptrackerpro.com/compare?select=nad Track in App: https://app.peptrackerpro.com/?add=nad ### SLU-PP-332 Low Evidence A synthetic ERRα/β/γ pan-agonist studied as an 'exercise mimetic' for endurance, fat oxidation, and metabolic health. Energy: https://peptrackerpro.com/benefits/energy Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/slu-pp-332 \+ Compare: https://peptrackerpro.com/compare?select=slu-pp-332 Track in App: https://app.peptrackerpro.com/?add=slu-pp-332 ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "Article", "headline": "MOTS-c vs SS-31", "description": "MOTS-c and SS-31 both target mitochondrial function but through entirely different mechanisms — MOTS-c as an endogenous signaling peptide and SS-31 as a synthetic membrane-targeting compound.", "dateModified": "2026-07-17", "author": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "publisher": { "@type": "Organization", "name": "PepTracker Pro", "logo": { "@type": "ImageObject", "url": "https://peptrackerpro.com/favicon.png" } }, "mainEntityOfPage": { "@type": "WebPage", "@id": "https://peptrackerpro.com/compare/mots-c-vs-ss-31" } } ] ```